Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Cawthron Institute Part Of International Collaboration To Develop World’s First Algae-based Local Anaesthetic

An algae-based pain medication that could improve the care of patients undergoing surgery is now closer to reality thanks to a collaboration between Cawthron Institute and medical researchers at Boston Children’s Hospital (a Harvard Medical School teaching hospital) and Chilean biotech company Proteus.

Cawthron Institute has announced they have developed a reliable and commercially scalable method for producing neosaxitoxin, a potent toxin from the paralytic shellfish toxin family, that can be combined with existing local anaesthetics for use as a local anaesthetic during and after surgery in post-operative patients.

All the local anaesthetics currently on the market are of two chemical classes, amino-amides and amino-esters, and they have changed very little over the past 50 years. Neosaxitoxin is the first member of the class of molecules called site 1 sodium channel blockers to be used in human clinical trials as a local anaesthetic.

Dr Johan Svenson, Cawthron Institute’s Science Leader for Algae and Bioactives research, says this is a globally significant scientific innovation that demonstrates Cawthron Institute’s world leading expertise in algal biotechnology and bioactive compound extraction and purification.

“Cawthron Institute has decades of experience producing compounds from algae for a range of scientific purposes. When we began our collaboration with researchers at Boston Children’s Hospital on the development of a neosaxitoxin-based pain medication, we were confident we could develop a reliable method of production of a high-purity product, even though no other research institute before us had achieved this feat,” Dr Svenson says.

“Producing commercial quantities of algae is a complex business – figuring out how to grow it is challenging enough, but then you still need the capability to extract and purify the bioactive compound, and in the case of neosaxitoxin, there was a chemical conversion step that we have developed and patented to achieve the level of purity required.”

Dr Charles Berde, co-founder of the Pain Treatment Center in the Department of Anesthesiology, Critical Care and Pain Medicine at Boston Children’s Hospital and Professor of Anaesthesia at Harvard Medical School, has been co-leading the development of a neosaxitoxin-based local anaesthetic for over two decades alongside his colleague Dr Daniel Kohane. Dr. Kohane is Director of the Laboratory for Biomaterials and Drug Delivery and Vice Chair for Research in the Department of Anesthesiology, Critical Care and Pain Medicine at Boston Children's Hospital and Professor of Anaesthesia at Harvard Medical School.

“Our motivation to develop this drug was to provide more effective pain relief for both children and adults following surgery. Opioid analgesics produce side-effects and can be addictive, so there is a great interest in developing better non-opioid approaches to pain relief,” Dr. Berde says.

Phase 1 clinical trials have been completed in the U.S. and Europe and showed very good safety and effectiveness in achieving more prolonged duration of local anaesthesia for infiltration and nerve blocks compared to the traditional local anesthetic, bupivacaine.

“The next steps are to take this drug through Phase 2 clinical trials, and although there is always uncertainty during the FDA approval process, we are optimistic about the prospects of neosaxitoxin and hope to see it approved and on the market in the coming years.”

Dr Berde is the keynote speaker at Cawthron Institute’s virtual Annual Thomas Cawthron Memorial Lecture on Tuesday 19 October. His address is open to the public and will live-stream via from 5.30pm on Tuesday 19 October.

“I’m very much looking forward to sharing this exciting research with a global audience, particularly those in New Zealand and Australia, and joining Cawthron researchers to talk about our collaboration during the live Q&A session with the audience.”

© Scoop Media

Business Headlines | Sci-Tech Headlines


Energy Resources Aotearoa: New Law On Decommissioning Could Be Costly Overkill
A new law on decommissioning oil and gas fields passed by Parliament today has good intentions but is overkill, according to Energy Resources Aotearoa. "We strongly support operators taking responsibility and paying the costs for decommissioning, which is what all good operators do," says chief executive John Carnegie... More>>

Commerce Commission: News Publishers’ Association Seeks Authorisation To Engage In Collective Bargaining

News Publishers’ Association of New Zealand Incorporated seeks authorisation and provisional authorisation to engage in collective bargaining with Facebook and Google. The Commerce Commission has received applications from News Publishers’ Association of New Zealand Incorporated (NPA) seeking authorisation and provisional authorisation on behalf of itself... More>>

Reserve Bank: MPC Continues To Reduce Monetary Stimulus
The Monetary Policy Committee agreed to raise the Official Cash Rate (OCR) to 0.75 per cent. The Committee agreed it remains appropriate to continue reducing monetary stimulus so as to maintain price stability and support maximum sustainable employment... More>>

PriceSpy: Producer Prices Increase
New Black Friday and Covid-19 Report* released by PriceSpy says people’s fear of stepping inside physical shops during big sales events like Black Friday has risen since last year; Kiwis are still planning to shop, but more than ever will do it online this year... More>>

NZ Skeptics Society: Announce Their 2021 Awards, And Dr Simon Thornley Wins The Bent Spoon

Every year the New Zealand Skeptics presents its awards to people and organisations who have impressed us or dismayed us, and this year it’s been hard to pick our winners because there have been so many choices!.. More>>

REINZ: Sales Volumes Leveling Out

Data released today by the Real Estate Institute of New Zealand (REINZ) shows there were 44 fewer lifestyle property sales (-2.6%) for the three months ended October 2021 than for the three months ended September 2021... More>>

BNZ: Auckland Retail Card Spending Bounces Back In Step Two
Bank of New Zealand (BNZ) card spending data released today shows one week of retail therapy at Alert Level 3 Step 2 has been enough to raise card spending in Auckland to levels greater than before the Delta lockdown... More>>